-
1
-
-
33645526144
-
Cancer statistics, 2006
-
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56 (2): 106-30
-
(2006)
CA Cancer J Clin
, vol.56
, Issue.2
, pp. 106-130
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
-
2
-
-
0031034106
-
HER-2/neu signal transduction in human breast and ovarian cancer
-
Reese DM, Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 1997; 15 (1): 1-8
-
(1997)
Stem Cells
, vol.15
, Issue.1
, pp. 1-8
-
-
Reese, D.M.1
Slamon, D.J.2
-
3
-
-
0024337144
-
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
-
Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244 (4905): 707-12
-
(1989)
Science
, vol.244
, Issue.4905
, pp. 707-712
-
-
Slamon, D.J.1
Godolphin, W.2
Jones, L.A.3
-
4
-
-
0032445260
-
HER-2/neu as a predictive marker of response to breast cancer therapy
-
Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998; 52 (1-3): 65-77
-
(1998)
Breast Cancer Res Treat
, vol.52
, Issue.1-3
, pp. 65-77
-
-
Pegram, M.D.1
Pauletti, G.2
Slamon, D.J.3
-
5
-
-
0027517374
-
Clinical significance of HER-2/neu oncogene amplification in primary breast cancer: The South Australian Breast Cancer Study Group
-
Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer: the South Australian Breast Cancer Study Group. J Clin Oncol 1993; 11 (10): 1936-42
-
(1993)
J Clin Oncol
, vol.11
, Issue.10
, pp. 1936-1942
-
-
Seshadri, R.1
Firgaira, F.A.2
Horsfall, D.J.3
-
6
-
-
0029662337
-
C-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
-
Carlomagno C, Perrone F, Gallo C, et al. C-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14 (10): 2702-8
-
(1996)
J Clin Oncol
, vol.14
, Issue.10
, pp. 2702-2708
-
-
Carlomagno, C.1
Perrone, F.2
Gallo, C.3
-
7
-
-
0028997307
-
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
-
Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10 (12): 2435-46
-
(1995)
Oncogene
, vol.10
, Issue.12
, pp. 2435-2446
-
-
Pietras, R.J.1
Arboleda, J.2
Reese, D.M.3
-
8
-
-
33646681444
-
HER2 and responsiveness of breast cancer to adjuvant chemotherapy
-
Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354 (20): 2103-11
-
(2006)
N Engl J Med
, vol.354
, Issue.20
, pp. 2103-2111
-
-
Pritchard, K.I.1
Shepherd, L.E.2
O'Malley, F.P.3
-
9
-
-
0028301750
-
Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: The influence of the pattern of immunostaining and adjuvant therapy
-
Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: the influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994; 73 (9): 2359-65
-
(1994)
Cancer
, vol.73
, Issue.9
, pp. 2359-2365
-
-
Tetu, B.1
Brisson, J.2
-
10
-
-
0026582760
-
HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis
-
Tiwari RK, Borgen PI, Wong GY, et al. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 1992; 12 (2): 419-25
-
(1992)
Anticancer Res
, vol.12
, Issue.2
, pp. 419-425
-
-
Tiwari, R.K.1
Borgen, P.I.2
Wong, G.Y.3
-
11
-
-
0031903646
-
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
-
Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16 (8): 2659-71
-
(1998)
J Clin Oncol
, vol.16
, Issue.8
, pp. 2659-2671
-
-
Pegram, M.D.1
Lipton, A.2
Hayes, D.F.3
-
12
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353 (16): 1659-72
-
(2005)
N Engl J Med
, vol.353
, Issue.16
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
-
13
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353 (16): 1673-84
-
(2005)
N Engl J Med
, vol.353
, Issue.16
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
-
14
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344 (11): 783-92
-
(2001)
N Engl J Med
, vol.344
, Issue.11
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
15
-
-
0026610881
-
Humanization of an anti-p185HER2 antibody for human cancer therapy
-
Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89 (10): 4285-9
-
(1992)
Proc Natl Acad Sci U S A
, vol.89
, Issue.10
, pp. 4285-4289
-
-
Carter, P.1
Presta, L.2
Gorman, C.M.3
-
16
-
-
0141645488
-
Mechanism of action of anti-HER2 monoclonal antibodies: Scientific update on trastuzumab and 2C4
-
Albanell J, Codony J, Rovira A, et al. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003; 532: 253-68
-
(2003)
Adv Exp Med Biol
, vol.532
, pp. 253-268
-
-
Albanell, J.1
Codony, J.2
Rovira, A.3
-
17
-
-
31644439702
-
Herceptin: Mechanisms of action and resistance
-
Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006; 232 (2): 123-38
-
(2006)
Cancer Lett
, vol.232
, Issue.2
, pp. 123-138
-
-
Nahta, R.1
Esteva, F.J.2
-
18
-
-
5144226211
-
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
-
Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6 (2): 117-27
-
(2004)
Cancer Cell
, vol.6
, Issue.2
, pp. 117-127
-
-
Nagata, Y.1
Lan, K.H.2
Zhou, X.3
-
19
-
-
32944460800
-
Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression
-
Henson ES, Hu X, Gibson SB. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin Cancer Res 2006; 12 (3 Pt 1): 845-53
-
(2006)
Clin Cancer Res
, vol.12
, Issue.3 PART 1
, pp. 845-853
-
-
Henson, E.S.1
Hu, X.2
Gibson, S.B.3
-
20
-
-
0037149539
-
Tumour biology: Herceptin acts as an anti-angiogenic cocktail
-
Izumi Y, Xu L, di Tomaso E, et al. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416 (6878): 279-80
-
(2002)
Nature
, vol.416
, Issue.6878
, pp. 279-280
-
-
Izumi, Y.1
Xu, L.2
di Tomaso, E.3
-
21
-
-
0032885461
-
Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu
-
Cooley S, Burns LJ, Repka T, et al. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 1999; 27 (10): 1533-41
-
(1999)
Exp Hematol
, vol.27
, Issue.10
, pp. 1533-1541
-
-
Cooley, S.1
Burns, L.J.2
Repka, T.3
-
22
-
-
0036467826
-
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
-
Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20 (3): 719-26
-
(2002)
J Clin Oncol
, vol.20
, Issue.3
, pp. 719-726
-
-
Vogel, C.L.1
Cobleigh, M.A.2
Tripathy, D.3
-
23
-
-
2942659576
-
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
-
Pegram MD, Konecny GE, O'Callaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96 (10): 739-49
-
(2004)
J Natl Cancer Inst
, vol.96
, Issue.10
, pp. 739-749
-
-
Pegram, M.D.1
Konecny, G.E.2
O'Callaghan, C.3
-
24
-
-
0034473393
-
Trastuzumab and chemotherapeutics: Drug interactions and synergies
-
Pegram MD, Lopez A, Konecny G, et al. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 2000; 27 (6 Suppl. 11): 21-5
-
(2000)
Semin Oncol
, vol.27
, Issue.6 SUPPL. 11
, pp. 21-25
-
-
Pegram, M.D.1
Lopez, A.2
Konecny, G.3
-
25
-
-
0036534121
-
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
-
Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20 (7): 1800-8
-
(2002)
J Clin Oncol
, vol.20
, Issue.7
, pp. 1800-1808
-
-
Esteva, F.J.1
Valero, V.2
Booser, D.3
-
26
-
-
22344446208
-
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group
-
Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23 (19): 4265-74
-
(2005)
J Clin Oncol
, vol.23
, Issue.19
, pp. 4265-4274
-
-
Marty, M.1
Cognetti, F.2
Maraninchi, D.3
-
27
-
-
23644440516
-
Docetaxel/trastuzumab combination therapy for the treatment of breast cancer
-
Nabholtz JM, Gligorov J. Docetaxel/trastuzumab combination therapy for the treatment of breast cancer. Expert Opin Pharmacother 2005; 6 (9): 1555-64
-
(2005)
Expert Opin Pharmacother
, vol.6
, Issue.9
, pp. 1555-1564
-
-
Nabholtz, J.M.1
Gligorov, J.2
-
28
-
-
34249941931
-
-
online, Available from URL:, Accessed Jun 26
-
Pusztai L, Esteva FJ. S0347: phase III (closed) [online]. Available from URL: http://www.swog.org/Visitors/View ProtocolDetails.asp?.ProtocolID=1969 [Accessed 2006 Jun 26]
-
(2006)
S0347: Phase III (closed)
-
-
Pusztai, L.1
Esteva, F.J.2
-
29
-
-
33947611168
-
Capecitabine and trastuzumab: A phase II study in HER2-overexpressing metastatic breast cancer (MBC) patients pretreated with anthracylines and/or taxanes [abstract no. 2033]
-
Schaller G, Bangemann N, Gonsch T, et al. Capecitabine and trastuzumab: a phase II study in HER2-overexpressing metastatic breast cancer (MBC) patients pretreated with anthracylines and/or taxanes [abstract no. 2033]. Breast Cancer Res Treat 2005; 94 Suppl. 1: S94
-
(2005)
Breast Cancer Res Treat
, vol.94
, Issue.SUPPL. 1
-
-
Schaller, G.1
Bangemann, N.2
Gonsch, T.3
-
30
-
-
30544441239
-
Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252
-
Perez EA, Suman VJ, Rowland KM, et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 2005; 6 (5): 425-32
-
(2005)
Clin Breast Cancer
, vol.6
, Issue.5
, pp. 425-432
-
-
Perez, E.A.1
Suman, V.J.2
Rowland, K.M.3
-
31
-
-
33745530224
-
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer
-
Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24 (18): 2786-92
-
(2006)
J Clin Oncol
, vol.24
, Issue.18
, pp. 2786-2792
-
-
Robert, N.1
Leyland-Jones, B.2
Asmar, L.3
-
33
-
-
33749344930
-
Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: An international phase II trial
-
Chan A, Martin M, Untch M, et al. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer 2006; 95 (7): 788-93
-
(2006)
Br J Cancer
, vol.95
, Issue.7
, pp. 788-793
-
-
Chan, A.1
Martin, M.2
Untch, M.3
-
34
-
-
33947543845
-
Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer
-
Bartsch R, Wenzel C, Altorjai G, et al. Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer. Breast Cancer Res Treat 2006; 102 (3): 375-81
-
(2006)
Breast Cancer Res Treat
, vol.102
, Issue.3
, pp. 375-381
-
-
Bartsch, R.1
Wenzel, C.2
Altorjai, G.3
-
35
-
-
33745552216
-
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multi-center phase II trial
-
Chia S, Clemons M, Martin LA, et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multi-center phase II trial. J Clin Oncol 2006; 24 (18): 2773-8
-
(2006)
J Clin Oncol
, vol.24
, Issue.18
, pp. 2773-2778
-
-
Chia, S.1
Clemons, M.2
Martin, L.A.3
-
36
-
-
0035257549
-
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials
-
Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001; 28 (1 Suppl. 3): 13-9
-
(2001)
Semin Oncol
, vol.28
, Issue.1 SUPPL. 3
, pp. 13-19
-
-
Slamon, D.1
Pegram, M.2
-
37
-
-
0038010542
-
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
-
Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97 (12): 2972-7
-
(2003)
Cancer
, vol.97
, Issue.12
, pp. 2972-2977
-
-
Bendell, J.C.1
Domchek, S.M.2
Burstein, H.J.3
-
38
-
-
27744440126
-
Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy
-
Burstein HJ, Lieberman G, Slamon DJ, et al. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005; 16 (11): 1772-7
-
(2005)
Ann Oncol
, vol.16
, Issue.11
, pp. 1772-1777
-
-
Burstein, H.J.1
Lieberman, G.2
Slamon, D.J.3
-
41
-
-
34249934853
-
Clinical characteristics and molecular makers predicting the development and outcome of breast cancer brain metastases [abstract no. 1049]
-
Melisko ME, Chew K, Baehner F, et al. Clinical characteristics and molecular makers predicting the development and outcome of breast cancer brain metastases [abstract no. 1049]. Breast Cancer Res Treat 2005; 94 Suppl. 1: S55
-
(2005)
Breast Cancer Res Treat
, vol.94
, Issue.SUPPL. 1
-
-
Melisko, M.E.1
Chew, K.2
Baehner, F.3
-
42
-
-
34249931260
-
Does HER2 positive breast cancer have a prelediction to metastasise to the brain? [abstract no. 4086]
-
Paterson C, McIntyre A, Canney PA. Does HER2 positive breast cancer have a prelediction to metastasise to the brain? [abstract no. 4086]. Breast Cancer Res Treat 2005; 94 Suppl. 1: S195
-
(2005)
Breast Cancer Res Treat
, vol.94
, Issue.SUPPL. 1
-
-
Paterson, C.1
McIntyre, A.2
Canney, P.A.3
-
43
-
-
34249941580
-
Breast cancer phenotype associated with a propensity for central nervous system (CNS) metastases [abstract no. 3020]
-
Tham YL, Sexton K, Kramer R, et al. Breast cancer phenotype associated with a propensity for central nervous system (CNS) metastases [abstract no. 3020]. Breast Cancer Res Treat 2005; 94 Suppl. 1: S131
-
(2005)
Breast Cancer Res Treat
, vol.94
, Issue.SUPPL. 1
-
-
Tham, Y.L.1
Sexton, K.2
Kramer, R.3
-
44
-
-
29744442709
-
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epipdermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31
-
Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epipdermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23 (31): 7811-9
-
(2005)
J Clin Oncol
, vol.23
, Issue.31
, pp. 7811-7819
-
-
Tan-Chiu, E.1
Yothers, G.2
Romond, E.3
-
47
-
-
33645720799
-
Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 positive early breast cancer patients: BCIRG 006 study [abstract no. 1]
-
Slamon DJ, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 positive early breast cancer patients: BCIRG 006 study [abstract no. 1]. Breast Cancer Res Treat 2005; 94 Suppl. 1: S5
-
(2005)
Breast Cancer Res Treat
, vol.94
, Issue.SUPPL. 1
-
-
Slamon, D.J.1
Eiermann, W.2
Robert, N.3
-
48
-
-
33344478381
-
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
-
Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354 (8): 809-20
-
(2006)
N Engl J Med
, vol.354
, Issue.8
, pp. 809-820
-
-
Joensuu, H.1
Kellokumpu-Lehtinen, P.L.2
Bono, P.3
-
49
-
-
33750878376
-
Trastuzumab (Herceptin) following adjuvant chemotherapy significantly improves disease-free survival in HER2-positive early breast cancer: The HERA trial [abstract no. 11]
-
The HERA Study Team
-
The HERA Study Team. Trastuzumab (Herceptin) following adjuvant chemotherapy significantly improves disease-free survival in HER2-positive early breast cancer: the HERA trial [abstract no. 11]. Breast Cancer Res Treat 2005; 94 Suppl. 1: S9
-
(2005)
Breast Cancer Res Treat
, vol.94
, Issue.SUPPL. 1
-
-
-
50
-
-
2942691785
-
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer
-
Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004; 96 (10): 759-69
-
(2004)
J Natl Cancer Inst
, vol.96
, Issue.10
, pp. 759-769
-
-
Pegram, M.D.1
Pienkowski, T.2
Northfelt, D.W.3
-
51
-
-
34249952357
-
-
Slamon D, Eiermann W, Robert N, et al. Phase III trial comparing AC-T with AC-TH with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: first interim efficacy analysis [online]. Available from URL: http://www.bcirg.org/NR/rdonlyres/ egyzmpkdila7fpxaupyr4m5g2e2ibz7yk7bt74qsdllsugkkcab6de7wtuyoz2bc4gn5uzspaf wssmbb5cdvzmkvv2e/BCIRG+SABCS+2005+powerpoint+.ppt [Accessed 2006 Jul 19]
-
Slamon D, Eiermann W, Robert N, et al. Phase III trial comparing AC-T with AC-TH with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: first interim efficacy analysis [online]. Available from URL: http://www.bcirg.org/NR/rdonlyres/ egyzmpkdila7fpxaupyr4m5g2e2ibz7yk7bt74qsdllsugkkcab6de7wtuyoz2bc4gn5uzspaf wssmbb5cdvzmkvv2e/BCIRG+SABCS+2005+powerpoint+.ppt [Accessed 2006 Jul 19]
-
-
-
-
52
-
-
33644688355
-
Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer: The FinHer Trial [abstract no. 2]
-
Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al. Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer: the FinHer Trial [abstract no. 2]. Breast Cancer Res Treat 2005; 94 Suppl. 1: S5
-
(2005)
Breast Cancer Res Treat
, vol.94
, Issue.SUPPL. 1
-
-
Joensuu, H.1
Kellokumpu-Lehtinen, P.-L.2
Bono, P.3
-
53
-
-
30544434252
-
Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracyline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting [abstract no. 1045]
-
Press MF, Bernstein L, Sauter G, et al. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracyline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting [abstract no. 1045]. Breast Cancer Res Treat 2005; 94 Suppl. 1: S54
-
(2005)
Breast Cancer Res Treat
, vol.94
, Issue.SUPPL. 1
-
-
Press, M.F.1
Bernstein, L.2
Sauter, G.3
-
54
-
-
23044480051
-
Topoisomerase II alpha expression in breast ductal invasive carcinomas and correlation with clinicopathological variables
-
Kalogeraki A, Ieromonachou P, Kafousi M, et al. Topoisomerase II alpha expression in breast ductal invasive carcinomas and correlation with clinicopathological variables. In Vivo 2005; 19 (5): 837-40
-
(2005)
In Vivo
, vol.19
, Issue.5
, pp. 837-840
-
-
Kalogeraki, A.1
Ieromonachou, P.2
Kafousi, M.3
-
55
-
-
0024651788
-
Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32
-
Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 1989; 4 (3): 362-6
-
(1989)
Genomics
, vol.4
, Issue.3
, pp. 362-366
-
-
Popescu, N.C.1
King, C.R.2
Kraus, M.H.3
-
56
-
-
0000676798
-
Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22
-
Tsai-Pflugfelder M, Liu LF, Liu AA, et al. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci U S A 1988; 85 (19): 7177-81
-
(1988)
Proc Natl Acad Sci U S A
, vol.85
, Issue.19
, pp. 7177-7181
-
-
Tsai-Pflugfelder, M.1
Liu, L.F.2
Liu, A.A.3
-
57
-
-
33745435244
-
Trastuzumab sensitivity of breast cancer with coamplification of HER2 and cMYC suggests proapoptotic function of dysregulated cMYC in vivo [abstract no. 46]
-
Kim C, Bryant J, Horne Z, et al. Trastuzumab sensitivity of breast cancer with coamplification of HER2 and cMYC suggests proapoptotic function of dysregulated cMYC in vivo [abstract no. 46]. Breast Cancer Res Treat 2005; 94 Suppl. 1: S6
-
(2005)
Breast Cancer Res Treat
, vol.94
, Issue.SUPPL. 1
-
-
Kim, C.1
Bryant, J.2
Horne, Z.3
-
58
-
-
0032850677
-
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
-
Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17 (9): 2639-48
-
(1999)
J Clin Oncol
, vol.17
, Issue.9
, pp. 2639-2648
-
-
Cobleigh, M.A.1
Vogel, C.L.2
Tripathy, D.3
-
60
-
-
33646712747
-
Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer
-
Nahta R, Yu D, Hung MC, et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3 (5): 269-80
-
(2006)
Nat Clin Pract Oncol
, vol.3
, Issue.5
, pp. 269-280
-
-
Nahta, R.1
Yu, D.2
Hung, M.C.3
-
61
-
-
28244432561
-
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
-
Nahta R, Yuan LX, Zhang B, et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65 (23): 11118-28
-
(2005)
Cancer Res
, vol.65
, Issue.23
, pp. 11118-11128
-
-
Nahta, R.1
Yuan, L.X.2
Zhang, B.3
-
62
-
-
0035915421
-
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
-
Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93 (24): 1852-7
-
(2001)
J Natl Cancer Inst
, vol.93
, Issue.24
, pp. 1852-1857
-
-
Lu, Y.1
Zi, X.2
Zhao, Y.3
-
63
-
-
31444444131
-
PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
-
Fujita T, Doihara H, Kawasaki K, et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 2006; 94 (2): 247-52
-
(2006)
Br J Cancer
, vol.94
, Issue.2
, pp. 247-252
-
-
Fujita, T.1
Doihara, H.2
Kawasaki, K.3
-
64
-
-
2542526069
-
P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells
-
Nahta R, Takahashi T, Ueno NT, et al. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004; 64 (11): 3981-6
-
(2004)
Cancer Res
, vol.64
, Issue.11
, pp. 3981-3986
-
-
Nahta, R.1
Takahashi, T.2
Ueno, N.T.3
-
65
-
-
23944476155
-
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
-
Burris HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23 (23): 5305-13
-
(2005)
J Clin Oncol
, vol.23
, Issue.23
, pp. 5305-5313
-
-
Burris, H.A.1
Hurwitz, H.I.2
Dees, E.C.3
-
66
-
-
32944461545
-
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
-
Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66 (3): 1630-9
-
(2006)
Cancer Res
, vol.66
, Issue.3
, pp. 1630-1639
-
-
Konecny, G.E.1
Pegram, M.D.2
Venkatesan, N.3
-
67
-
-
30544450275
-
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
-
Xia W, Gerard CM, Liu L, et al. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005; 24 (41): 6213-21
-
(2005)
Oncogene
, vol.24
, Issue.41
, pp. 6213-6221
-
-
Xia, W.1
Gerard, C.M.2
Liu, L.3
-
68
-
-
33845886440
-
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
-
Geyer GE, Forster JM, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355 (26): 2733-43
-
(2006)
N Engl J Med
, vol.355
, Issue.26
, pp. 2733-2743
-
-
Geyer, G.E.1
Forster, J.M.2
Lindquist, D.3
-
71
-
-
11244310533
-
Targeting c-erbB2 and other receptors of the c-erbB family: Rationale and clinical applications
-
Bianco AR. Targeting c-erbB2 and other receptors of the c-erbB family: rationale and clinical applications. J Chemother 2004; 16 Suppl. 4: 52-4
-
(2004)
J Chemother
, vol.16
, Issue.SUPPL. 4
, pp. 52-54
-
-
Bianco, A.R.1
-
72
-
-
1842605531
-
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
-
Franklin MC, Carey KD, Vajdos FF, et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5 (4): 317-28
-
(2004)
Cancer Cell
, vol.5
, Issue.4
, pp. 317-328
-
-
Franklin, M.C.1
Carey, K.D.2
Vajdos, F.F.3
-
73
-
-
21244467171
-
-
Willems A, Gauger K, Henrichs C, et al. Antibody therapy for breast cancer. Anticancer Res 2005; 25 (3A): 1483-9
-
Willems A, Gauger K, Henrichs C, et al. Antibody therapy for breast cancer. Anticancer Res 2005; 25 (3A): 1483-9
-
-
-
-
74
-
-
0025318271
-
Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product
-
Fendly BM, Winget M, Hudziak RM, et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990; 50 (5): 1550-8
-
(1990)
Cancer Res
, vol.50
, Issue.5
, pp. 1550-1558
-
-
Fendly, B.M.1
Winget, M.2
Hudziak, R.M.3
-
75
-
-
34249944855
-
Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells
-
Wang K, Ma Q, Ren Y, et al. Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells. Oncol Rep 2007; 17 (1): 89-96
-
(2007)
Oncol Rep
, vol.17
, Issue.1
, pp. 89-96
-
-
Wang, K.1
Ma, Q.2
Ren, Y.3
-
76
-
-
34249943420
-
A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours
-
abstract no. 2074, 97s
-
Agus DB, Terlizzi E, Stopfer P, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours [abstract no. 2074]. 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2-6; Atlanta (GA). Proc Am Soc Clin Oncol 2006; 24 (18S): 97s
-
42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2-6; Atlanta (GA). Proc Am Soc Clin Oncol 2006; 24 (18S)
-
-
Agus, D.B.1
Terlizzi, E.2
Stopfer, P.3
-
77
-
-
34249931027
-
A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours
-
abstract no. 3027, 127s
-
Shaw H, Plummer R, Vidal L, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours [abstract no. 3027]. 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2-6; Atlanta (GA). Proc Am Soc Clin Oncol 2006; 24 (18S): 127s
-
42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2-6; Atlanta (GA). Proc Am Soc Clin Oncol 2006; 24 (18S)
-
-
Shaw, H.1
Plummer, R.2
Vidal, L.3
-
78
-
-
34249944752
-
Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer [abstract no. 1091]
-
Iwata H, Toi M, Fujiwara Y, et al. Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer [abstract no. 1091]. Breast Cancer Res Treat 2006; 100 Suppl. 1: S68
-
(2006)
Breast Cancer Res Treat
, vol.100
, Issue.SUPPL. 1
-
-
Iwata, H.1
Toi, M.2
Fujiwara, Y.3
-
80
-
-
34249885718
-
A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC) [abstract no. 1]
-
Cristofanilli M, Boussen H, Baselga J, et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC) [abstract no. 1]. Breast Cancer Res Treat 2006; 100 Suppl. 1: S5
-
(2006)
Breast Cancer Res Treat
, vol.100
, Issue.SUPPL. 1
-
-
Cristofanilli, M.1
Boussen, H.2
Baselga, J.3
-
81
-
-
33747105022
-
A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab [abstract no. 1073]
-
Storniolo AM, Burris III H, Overmoyer B, et al. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab [abstract no. 1073]. Breast Cancer Res Treat 2005; 94 Suppl. 1: S64
-
(2005)
Breast Cancer Res Treat
, vol.94
, Issue.SUPPL. 1
-
-
Storniolo, A.M.1
Burris III, H.2
Overmoyer, B.3
-
82
-
-
1942474587
-
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
-
Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004; 64 (7): 2343-6
-
(2004)
Cancer Res
, vol.64
, Issue.7
, pp. 2343-2346
-
-
Nahta, R.1
Hung, M.C.2
Esteva, F.J.3
-
83
-
-
20244378677
-
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer
-
Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005; 23 (11): 2534-43
-
(2005)
J Clin Oncol
, vol.23
, Issue.11
, pp. 2534-2543
-
-
Agus, D.B.1
Gordon, M.S.2
Taylor, C.3
-
84
-
-
33645651433
-
A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer
-
Walshe JM, Denduluri N, Berman AW, et al. A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. Clin Breast Cancer 2006; 6 (6): 535-9
-
(2006)
Clin Breast Cancer
, vol.6
, Issue.6
, pp. 535-539
-
-
Walshe, J.M.1
Denduluri, N.2
Berman, A.W.3
-
85
-
-
33749003463
-
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status
-
Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006; 24 (26): 4324-32
-
(2006)
J Clin Oncol
, vol.24
, Issue.26
, pp. 4324-4332
-
-
Gordon, M.S.1
Matei, D.2
Aghajanian, C.3
-
86
-
-
33746905493
-
Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer
-
s
-
Johnson BE, Janne PA. Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer. Clin Cancer Res 2006; 12 (14 Pt 2): 4436-40s
-
(2006)
Clin Cancer Res
, vol.12
, Issue.14 PART 2
, pp. 4436-4440
-
-
Johnson, B.E.1
Janne, P.A.2
-
87
-
-
33847147996
-
The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers
-
Marcom PK, Isaacs C, Harris L, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007; 102 (1): 43-9
-
(2007)
Breast Cancer Res Treat
, vol.102
, Issue.1
, pp. 43-49
-
-
Marcom, P.K.1
Isaacs, C.2
Harris, L.3
-
88
-
-
34247243265
-
Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER 2-amplified breast cancer [abstract no. 301]
-
Pegram M, Chan D, Dichmann RA, et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER 2-amplified breast cancer [abstract no. 301]. Breast Cancer Res Treat 2006; 100 Suppl. 1: S28
-
(2006)
Breast Cancer Res Treat
, vol.100
, Issue.SUPPL. 1
-
-
Pegram, M.1
Chan, D.2
Dichmann, R.A.3
-
89
-
-
34249944615
-
Selective inhibition of ADAM metalloproteases blocks Her-2 extracellular domain (ECD) clevage and potentiates trastuzumab in blocking the growth of Her-2 overexpressing breast cancer cells [abstract no. 6051]
-
Liu X, Wang Q, Yang G, et al. Selective inhibition of ADAM metalloproteases blocks Her-2 extracellular domain (ECD) clevage and potentiates trastuzumab in blocking the growth of Her-2 overexpressing breast cancer cells [abstract no. 6051]. Breast Cancer Res Treat 2005; 94 Suppl. 1: S265
-
(2005)
Breast Cancer Res Treat
, vol.94
, Issue.SUPPL. 1
-
-
Liu, X.1
Wang, Q.2
Yang, G.3
-
92
-
-
34249934030
-
A phase I vaccine trial of a HER-2/neu peptide incorporated into PLG microspheres in patients with advanced stage HER2-expressing cancers. [2572]. 42nd Annual Meeting of the American Society of Clinical Oncology
-
Jun 2-6; 118s
-
Salazar LG, Murray JL, Disis ML, et al. A phase I vaccine trial of a HER-2/neu peptide incorporated into PLG microspheres in patients with advanced stage HER2-expressing cancers. [2572]. 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2-6; Atlanta (GA). Proc Am Soc Clin Oncol 2006; 24 (18S): 118s
-
(2006)
Atlanta (GA). Proc Am Soc Clin Oncol 2006; 24 (18S)
-
-
Salazar, L.G.1
Murray, J.L.2
Disis, M.L.3
-
93
-
-
32844457528
-
Biomolecular markers of breast cancer
-
Nicolini A, Carpi A, Tarro G. Biomolecular markers of breast cancer. Front Biosci 2006; 11: 1818-43
-
(2006)
Front Biosci
, vol.11
, pp. 1818-1843
-
-
Nicolini, A.1
Carpi, A.2
Tarro, G.3
-
94
-
-
34249948059
-
Lapatinib plus capecitabine shows superior efficacy compared to capecitabine alone in patients with ErbB2 positive advanced or metastatic breast cancer-initial biomarker data [abstract no. 2]
-
Cameron D, Stein S, Zaks T, et al. Lapatinib plus capecitabine shows superior efficacy compared to capecitabine alone in patients with ErbB2 positive advanced or metastatic breast cancer-initial biomarker data [abstract no. 2]. Breast Cancer Res Treat 2006; 100 Suppl. 1: S5
-
(2006)
Breast Cancer Res Treat
, vol.100
, Issue.SUPPL. 1
-
-
Cameron, D.1
Stein, S.2
Zaks, T.3
-
95
-
-
31544465529
-
p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer
-
Saez R, Molina MA, Ramsey EE, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006; 12 (2): 424-31
-
(2006)
Clin Cancer Res
, vol.12
, Issue.2
, pp. 424-431
-
-
Saez, R.1
Molina, M.A.2
Ramsey, E.E.3
|